Literature DB >> 7889639

Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.

H Lefebvre1, C Noblet, N Moore, L M Wolf.   

Abstract

A patient presented with paroxysmal hypertension and typical clinical features of phaeochromocytoma, but with a normal adrenal computed tomographic scan and much higher plasma noradrenaline than adrenaline concentrations. Urinary vanillylmandelic acid concentrations were only moderately elevated. This syndrome probably arose as a consequence of an interaction between the monoamine oxidase inhibitor selegiline, the sympathomimetic agent ephedrine, and a tricyclic antidepressant. The mechanism of the interaction is thought to be related to increased sympathetic release of noradrenaline by ephedrine, inhibition of catabolism by selegiline, and inhibition of reuptake of noradrenaline by the tricyclic. Although newer selective monoamine oxidase inhibitors are considered to be safer than earlier non-selective inhibitors, they can also contribute to drug interactions mimicking phaeochromocytoma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7889639     DOI: 10.1111/j.1365-2265.1995.tb02604.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  10 in total

Review 1.  Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma.

Authors:  G Eisenhofer; T T Huynh; M Hiroi; K Pacak
Journal:  Rev Endocr Metab Disord       Date:  2001-08       Impact factor: 6.514

Review 2.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

3.  Unusual clinical manifestation of pheochromocytoma in a MEN2A patient.

Authors:  M Guerrieri; S Filipponi; G Arnaldi; M Giovagnetti; E Lezoche; F Mantero; A Taccaliti
Journal:  J Endocrinol Invest       Date:  2002-01       Impact factor: 4.256

Review 4.  Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.

Authors:  B K Young; R Camicioli; L Ganzini
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

Review 5.  Drug interactions of clinical importance. An updated guide.

Authors:  D I Quinn; R O Day
Journal:  Drug Saf       Date:  1995-06       Impact factor: 5.606

Review 6.  Monoamine oxidase inhibitors. An update on drug interactions.

Authors:  M G Livingston; H M Livingston
Journal:  Drug Saf       Date:  1996-04       Impact factor: 5.606

7.  Diagnosis of pheochromocytoma in the setting of Parkinson disease.

Authors:  Shyamal H Mehta; Rajan Prakash; L Michael Prisant; Carlos M Isales; John C Morgan; Hadyn Williams; Kapil D Sethi
Journal:  Nat Rev Neurol       Date:  2009-06       Impact factor: 42.937

Review 8.  Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management.

Authors:  Graeme Eisenhofer; Graham Rivers; Alejandro L Rosas; Zena Quezado; William M Manger; Karel Pacak
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 9.  Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.

Authors:  E H Heinonen; V Myllylä
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

10.  Monoamino oxidase alleles correlate with the presence of essential hypertension among hypogonadic patients.

Authors:  José Luis Royo; Daniel Castellano-Castillo; Maximiliano Ruiz-Galdon; María Molina-Vega; Fernando Cardona; Francisco J Tinahones; José C Fernández-García; Armando Reyes-Engel
Journal:  Mol Genet Genomic Med       Date:  2019-11-19       Impact factor: 2.183

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.